AIM IMMUNOTECH INC. Unrealized Gain (Loss) on Securities
AIM IMMUNOTECH INC. (AIM) reported Unrealized Gain (Loss) on Securities of -$12.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Income Statement › Other Income
us-gaap:UnrealizedGainLossOnSecurities · last filed 2020-11-12
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for the quarter ending 2020-09-30 was -$75.00K.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for the quarter ending 2020-06-30 was $59.00K.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for the quarter ending 2020-03-31 was $4.00K.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for fiscal 2018 was -$14.00K, a 187.50% decline from fiscal 2017.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for fiscal 2017 was $16.00K, a 82.61% decline from fiscal 2016.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for fiscal 2016 was $92.00K, a 46.03% increase from fiscal 2015.
- AIM IMMUNOTECH INC. unrealized gain (loss) on securities for fiscal 2015 was $63.00K.
| Period end | Unrealized Gain (Loss) on Securities 3 month | Unrealized Gain (Loss) on Securities 6 month | Unrealized Gain (Loss) on Securities 9 month | Unrealized Gain (Loss) on Securities 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$16.00K derived: sum of 2 quarters · filed 2020-11-12 | -$12.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $63.00K 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | $4.00K 10-Q · filed 2020-05-14 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.00K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $1.00K 10-Q · filed 2019-08-14 | |||
| 2018-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $6.00K derived: sum of 2 quarters · filed 2019-11-14 | -$2.00K derived: sum of 3 quarters · filed 2019-11-14 | -$14.00K 10-K · filed 2019-04-01 |
| 2018-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $32.00K derived: sum of 2 quarters · filed 2019-11-14 | $20.00K 10-Q · filed 2019-11-14 | -$4.00K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$20.00K 10-Q · filed 2019-08-14 | -$44.00K derived: sum of 3 quarters · filed 2019-08-14 | -$33.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$12.00K 10-Q · filed 2019-05-15 | -$36.00K derived: sum of 2 quarters · filed 2019-05-15 | -$25.00K derived: sum of 3 quarters · filed 2019-05-15 | -$8.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$13.00K derived: sum of 2 quarters · filed 2019-04-01 | $4.00K derived: sum of 3 quarters · filed 2019-04-01 | $16.00K 10-K · filed 2019-04-01 |
| 2017-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $28.00K derived: sum of 2 quarters · filed 2018-11-14 | $40.00K 10-Q · filed 2018-11-14 | $20.00K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $29.00K 10-Q · filed 2018-08-14 | $9.00K derived: sum of 3 quarters · filed 2018-08-14 | -$63.00K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $12.00K 10-Q · filed 2018-05-15 | -$8.00K derived: sum of 2 quarters · filed 2018-05-15 | -$80.00K derived: sum of 3 quarters · filed 2018-05-15 | -$43.00K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | -$92.00K derived: sum of 2 quarters · filed 2018-03-30 | -$55.00K derived: sum of 3 quarters · filed 2018-03-30 | $92.00K 10-K · filed 2018-03-30 |
| 2016-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$35.00K derived: sum of 2 quarters · filed 2017-11-14 | $112.00K 10-Q · filed 2017-11-14 | $416.00K derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $184.00K 10-Q · filed 2017-08-14 | $488.00K derived: sum of 3 quarters · filed 2018-03-30 | $273.00K derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-03-31 | $147.00K 10-Q · filed 2017-05-15 | $451.00K derived: sum of 2 quarters · filed 2018-03-30 | $236.00K derived: sum of 3 quarters · filed 2018-03-30 | $99.00K derived: sum of 4 quarters · filed 2018-03-30 |
| 2015-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $89.00K derived: sum of 2 quarters · filed 2018-03-30 | -$48.00K derived: sum of 3 quarters · filed 2018-03-30 | $63.00K 10-K · filed 2018-03-30 |
| 2015-09-30 | -$215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$352.00K derived: sum of 2 quarters · filed 2016-11-14 | -$241.00K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$26.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $111.00K 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | -$46.00K 10-K · filed 2017-03-31 | |||
| 2013-12-31 | -$71.00K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |